- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanosonics Limited (ASX:NAN) is pleased to announce that it has commenced production and commercial sale of its breakthrough Trophon(TM) EPR ultrasound probe disinfector system, through distribution partners in New Zealand and Australia.
Shipments, comprising Trophon EPR systems and NanoNebulant(TM) consumables, have been allocated to fulfil purchase orders already placed on the distribution partners by their customers, clinical end-users of the products.
The Company has undertaken a full sales launch to ultrasound professionals, including trade advertising and sales presentations to key opinion leaders and clinics throughout Australasia. Sales demand is being driven by the unique value proposition provided by the Trophon EPR system in the medical ultrasound market. A contributing factor to this demand is the greater awareness and vigilance of mandated legislation, regulatory requirements and the significant OH&S issues facing hospital and clinic staff.
The Trophon EPR is now being included in tenders submitted by the Original Equipment Manufacturers (OEMs). Further, the Company has been advised that the Trophon EPR has been incorporated as a condition in several new Government tenders, both in Australia and internationally.
Nanosonics has commenced a broad range of pre-launch activities in Europe, with first shipments expected in the next quarter of 2009. The Company has established a strong dealer network throughout Europe, each of whom has committed to commercial purchases of the Trophon EPR system to support the European launch.
It is expected that the Trophon EPR system will be launched in the near term into certain key markets in Asia, where the regulatory requirements for sale have already been met.
Sales demand in this region is being influenced by the recent Guidelines issued by the US Centre for Disease Control (CDC),
Nanosonics now has substantial technical resources available to pursue additional commercial products based upon its novel NanoNebulant platform. Prototyping is now well advanced for several new devices which address substantial global market needs.
The Company is in commercial discussions with both equipment manufacturers and other potential strategic partners, with a view to bringing devices to market where the Company's technology can deliver automated, safe, effective and environmentally sound solutions to the growing range of markets in healthcare and beyond.
About Nanosonics Limited
Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.
Initial market applications are designed for the reprocessing of reusable medical instruments. The Company’s first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.
Chief Financial Officer
Tel: +61-2-8063 1600
Copyright © Nanosonics LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016